H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $32 from $26 and keeps a Buy rating on the shares. The company’s FDA Type B meeting outcome delineates a path to registration, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
- MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
- De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026
- MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
- Unusually active option classes on open January 8th